Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2015

Open Access 01-09-2015 | Original Article

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Authors: Yolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, Rosa Álvarez, Andrés Muñoz, Olatz Olariaga, María José Tamés, Begoña Muros, María Jose Lecumberri, Jaime Feliu, Purificación Martínez, Juan Carlos Adansa, María José Martínez, Rafael López, Ana Blasco, Pere Gascón, Virginia Calvo, Pablo Luna, Joaquín Montalar, Patricia Del Barrio, María Victoria Tornamira

Published in: Supportive Care in Cancer | Issue 9/2015

Login to get access

Abstract

Purpose

This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV.

Methods

Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints.

Results

Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients’ diary.

Conclusion

Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.
Appendix
Available only for authorised users
Literature
1.
Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208PubMedCrossRef
2.
de Boer-Dennert M, de Wit R, Schmitz PIM, Djontono J, van Beurden V, Stoter G, Verweij J (1997) Patient perception of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMedCentralPubMedCrossRef
3.
Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE (2001) The changeable nature of patients’ fear regarding chemotherapy: implications for palliative care. J Pain Symptom Manag 21:113–120CrossRef
4.
Wagland R, Richardson A, Armes J, Hankins M, Lennan E, Griffiths P (2014) Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review Eur J Cancer Care. doi: 10.​1111/​ecc.​12246
5.
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198PubMedCrossRef
6.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(suppl 5):v232–v243. doi:10.​1093/​annonc/​mdq194 PubMedCrossRef
7.
Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22:30–8PubMedCrossRef
8.
Hesketh PJ (2008) Drug therapy: chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494PubMedCrossRef
9.
Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202PubMedCrossRef
10.
Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag 20:113–121CrossRef
11.
Perwitasari DA, Atthobari J, Mustofa M, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, Nortier JW, Guchelaar HJ, Kaptein AA (2012) Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer. Int J Gynecol Cancer 22:139–45PubMedCrossRef
12.
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478PubMedCrossRef
13.
Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20:107–117PubMedCentralPubMedCrossRef
14.
15.
Basch E, Snyder C, McNiff K, Brown R, Maddux S, Smith ML, Atkinson TM, Howell D, Chiang A, Wood W, Levitan N, Wu AW, Krzyzanowska M (2014) Patient-reported outcome performance measures in oncology. J Oncol Pract 10:209–211PubMedCrossRef
16.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268PubMedCrossRef
17.
Gómez-Raposo C, Feliú-Batle J, González-Barón M (2006) Prevención y control de las náuseas y vómitos inducidos por quimioterapia. Med Clin 126:143–51CrossRef
18.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, On behalf of the Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090–3098. doi:10.​1002/​cncr.​11433 PubMedCrossRef
19.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112–9PubMedCrossRef
20.
Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalén J, Jung H, Liu YP, Burke TA, Keefe DM (2015) Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 23:263–72PubMedCrossRef
21.
Schnell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 8:187–98PubMedCrossRef
22.
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992PubMedCrossRef
23.
Antiemesis. NCCN practice guidelines in oncology v2 2014. National Comprehensive Cancer Network www.​nccn.​org. Last accessed September 4, 2014
24.
Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–47PubMedCrossRef
25.
Navari RM (2007) Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Commun Oncol 4:3–11
26.
De Angelis V, Roila F, Sabbatini R, Italian Group for Antiemetic Research et al (2003) Cancer chemotherapy (CT)-induced delayed emesis: antiemetic prescriptions in clinical practice (abstract 2971). J Clin Oncol 22:739
27.
Rubenstein EB, Litke SE, Jose MA (2002) Chemotherapy-induced nausea and emesis in the 5HT3 era: a national survey of hematologists/oncologists [abstract]. Proc Am Soc Clin Oncol 21:260b
28.
Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Cancer Care 19:1983–90. doi:10.​1007/​s00520-010-1042-3 CrossRef
29.
Metadata
Title
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Authors
Yolanda Escobar
Gerardo Cajaraville
Juan Antonio Virizuela
Rosa Álvarez
Andrés Muñoz
Olatz Olariaga
María José Tamés
Begoña Muros
María Jose Lecumberri
Jaime Feliu
Purificación Martínez
Juan Carlos Adansa
María José Martínez
Rafael López
Ana Blasco
Pere Gascón
Virginia Calvo
Pablo Luna
Joaquín Montalar
Patricia Del Barrio
María Victoria Tornamira
Publication date
01-09-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2809-3

Other articles of this Issue 9/2015

Supportive Care in Cancer 9/2015 Go to the issue

Original Article

The Female Sexual Functioning Index (FSFI): evaluation of acceptability, reliability, and validity in women with breast cancer

Original Article

Survivorship care plans and time since diagnosis: factors that contribute to who breast cancer survivors see for the majority of their care

Original Article

Factors influencing response to lymphedema treatment in patients with breast cancer-related lymphedema

Original Article

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines

Original Article

Impact of marital coping on the relationship between body image and sexuality among breast cancer survivors

Original Article

Is long-term cancer survivors’ quality of life comparable to that of the general population? An italian study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits